[CAS NO. 80433-71-2] LevoleucovorinCalcium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [80433-71-2]

Catalog

HY-13667

Brand

MCE

CAS

80433-71-2

DESCRIPTION [80433-71-2]

Overview

MDL	MFCD08704249
Molecular Weight	511.50
Molecular Formula	C20H21CaN7O7
SMILES	O=C1C2=C(NC[C@H](CNC3=CC=C(C(N[C@H](C([O-])=O)CCC([O-])=O)=O)C=C3)N2C=O)NC(N)=N1.[Ca+2]

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.

Summary

Levoleucovorin Calcium (Calcium levofolinate), a levo isoform of Leucovorin Calcium (HY-13664), possesses antineoplastic effects. Levoleucovorin Calcium is also an augmentor of 5-fluorouracil (HY-90006) cytotoxicity against cancer ^[1] ^[2] .

In Vivo

Levoleucovorin Calcium (6, 20 or 60 mg/kg/day; i.v.; for 4 weeks) enhances the toxicity of 5-Fluorouracil ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Crj:CD(SD)BR rats (5 weeks) ^[2]
Dosage:	6, 20 or 60 mg/kg/day
Administration:	i.v.; for 4 weeks (combined with 10 mg/kg/day 5-Fluorouracil )
Result:	Decreased the RBC counts, increased extramedullary hematopoiesis and enhanced the suppression of lymphatic organs. Induced the potentiation in the toxicity of 5-Fluorouracil appeared to be mainly immuno-suppression and myelosuppression, which were related to the anti-tumor activity of 5-Fluorouracil.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04949256	Merck Sharp & Dohme LLC\|Eisai Inc.	Metastatic Esophageal Squamous Cell Carcinoma	July 28, 2021	Phase 3
NCT04210115	Merck Sharp & Dohme LLC	Esophageal Squamous Cell Carcinoma (ESCC)\|Gastroesophageal Junction Carcinoma (GEJC)\|Esophageal Adenocarcinoma (EAC)	February 28, 2020	Phase 3
NCT01882868	Sanofi\|Regeneron Pharmaceuticals	Colorectal Cancer Metastatic	July 2013	Phase 2
NCT03698461	Asan Medical Center\|Hoffmann-La Roche	Colorectal Neoplasms\|Neoplasm Metastasis\|Colonic Neoplasms\|Rectal Neoplasms	May 15, 2019	Phase 2
NCT02497157	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan\|Hiroshima Prefectural Hospital\|National Hospital Organization Shikoku Cancer Center	Metastatic Colorectal Cancer	May 21, 2015	Phase 2
NCT04060017	Rossignol Medical Center\|State University of New York - Downstate Medical Center\|United States Department of Defense\|Southwest Autism Research & Resource Center	Autism Spectrum Disorder\|Language Disorders	September 22, 2020	Phase 2
NCT04745988	National Cancer Center Hospital East\|Merck Sharp & Dohme LLC	Gastric Cancer	November 11, 2021	Phase 2
NCT05253651	Seagen Inc.\|Merck Sharp & Dohme LLC	Colorectal Neoplasms	November 30, 2022	Phase 3
NCT04456699	Merck Sharp & Dohme LLC	Metastatic Colorectal Cancer	August 19, 2020	Phase 3
NCT03387592	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	Neuroendocrine Carcinoma	March 6, 2017	Phase 2
NCT03045770	Fujian Cancer Hospital	Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction	February 10, 2017	Not Applicable
NCT03222089	Fujian Cancer Hospital	Metastatic Colorectal Cancer	July 20, 2017	Phase 2
NCT05546853	University Hospital, Grenoble\|NETRIS Pharma	Pancreatic Ductal Adenocarcinoma	November 2022	Phase 1
NCT02697058	Institut de Recherches Internationales Servier\|ADIR, a Servier Group company\|Servier	Metastatic Pancreatic Cancer	March 30, 2016	Phase 2
NCT04776655	Azienda Unità Sanitaria Locale Reggio Emilia\|Istituto Di Ricerche Farmacologiche Mario Negri\|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale	Colorectal Cancer\|Metastatic Colorectal Cancer\|RAS Mutation	April 30, 2021	Phase 3
NCT01286818	Eli Lilly and Company	Colorectal Carcinoma	February 2011	Phase 1
NCT04060030	Rossignol Medical Center\|Autism Speaks\|State University of New York - Downstate Medical Center\|Southwest Autism Research & Resource Center	Autism Spectrum Disorder\|Language Disorders	October 8, 2020	Phase 2
NCT02641873	Sumitomo Pharma Co., Ltd.	Metastatic Colorectal Cancer	December 2015	Phase 1
NCT01681472	Isofol Medical AB	Colonic Neoplasms	September 2012	Phase 1\|Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 10 mg/mL ( 19.55 mM ; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9550 mL	9.7752 mL	19.5503 mL
5 mM	0.3910 mL	1.9550 mL	3.9101 mL
10 mM	0.1955 mL	0.9775 mL	1.9550 mL

* Please refer to the solubility information to select the appropriate solvent.

References

Synonyms

L-Glutamic acid, N-[4-[[[(6S)-2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-, calcium salt (1:1)

L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt (1:1), (S)-

L-Glutamic acid, N-[4-[[[(6S)-2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl]methyl]amino]benzoyl]-, calcium salt (1:1)

(S)-Leucovorin calcium salt (1:1)

Calcium (6S)-folinate

Levoleucovorin calcium

Isovorin

Calcium levofolinate

5-Formyl-(6S)-tetrahydrofolate calcium salt

L-Folinic acid calcium salt

CL 307782

Elvorine